Thrive Capital

Selected reporting and mythical analysis on thrive capital.

In Brief
Mar 3, 2026

Anduril's $60 Billion Valuation Quest: When Your Defense Tech Dreams Are Funded by Unicorns and Monopoly Money

Anduril's quest for a $60 billion valuation in its latest funding round is a hilarious satire on Silicon Valley's obsession with inflated numbers and defense tech absurdity.

AI
Jan 31, 2026

Physical Intelligence: Silicon Valley's Bold Quest to Build Robot Brains That Might Actually Remember Where They Put Your Coffee

Silicon Valley's Physical Intelligence startup promises robot brains with emotional depth and existential crises. Will they revolutionize tech or just get lost in your garage?

Fundraising
Oct 8, 2025

Base Power's $1B Battery Boondoggle Promises to Turn Your Home Into a Power-Hungry Beast

Base Power's $1B funding to deploy home batteries everywhere is satirized in this hilarious take on energy tech, featuring exaggerated risks and absurd benefits that will leave you laughing and questioning your power choices.

AI
Jun 5, 2025

Cursor’s Anysphere Hits $9.9B Valuation: Now Worth More Than Small Countries

Cursor’s Anysphere's $9.9B valuation has everyone questioning reality. How does a 3-year-old startup soar past $500M ARR? Magic, probably.

Sponsored
Mar 31, 2026

Skylum's Luminar & X-Membership: Because Your Selfies Deserve a Red Carpet Entrance

In an era where your camera roll looks like a tragic comedy, Skylum’s Luminar teams up with the exclusive X-Membership to transform your humble snapshots into blockbuster-worthy works of art—becaus...

Sponsored Content
AI
Jun 2, 2025

AI to the Rescue: Console's $6.2M Miracle Cure for IT Teams Who Just Can't Even Anymore

Console's $6.2M AI solution promises to free IT teams from mundane tasks, but will it really save them from their existential dread? Find out in this hilariously satirical take.

The future is glitched.

Join 50,000+ readers getting our weekly dose of tech insights and playful commentary.

BY JOINING, YOU AGREE TO OUR IMAGINATIVE TERMS.